Acute and Chronic Kidney Disease
[Acute and Chronic Kidney Disease]
EPTIS Ringversuch Nr. 1615596 | Letze Änderung 2026-09-24 | URL: https://www.eptis.bam.de/pts1615596 https://www.eptis.bam.de/pts1615596
| Name des Anbieters | ||||||||||||||||||||||||||||||||||
| Name des Anbieters | Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust | |||||||||||||||||||||||||||||||||
| Ansässig in | United Kingdom | |||||||||||||||||||||||||||||||||
| Sprache(n) | English | |||||||||||||||||||||||||||||||||
| Anmerkungen | There are a number of elements to this Scheme (1) Creatinine for CKD (eGFR), (2) Creatinine for AKI, (3) Cystatin C and (4) KFRE pilot (KFRE is not accredited to ISO/IEC 17043:2023). The overall objective of all elements is to provide EQA for monitoring of renal assays and associated pathways. The Scheme provides EQA specimens targeted at specific Creatinine concentrations, with no other manipulation present. This allows wider investigation of Creatinine assays and how creatinine impacts eGFR equations and AKI pathways. This Scheme will test your eGFR equation and AKI algorithm in your LIMS. We would recommend that you have one registration per Creatinine assay as this will allow you to assess how any variation in Creatinine affects eGFR and AKI across your service. | |||||||||||||||||||||||||||||||||
| Klassifizierung | ||||||||||||||||||||||||||||||||||
| Produktgruppen |
Health care / medical devices
|
|||||||||||||||||||||||||||||||||
| Prüfgebiete |
Medical analysis
|
|||||||||||||||||||||||||||||||||
| Technische Einzelheiten | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
| Ringversuchsziele | ||||||||||||||||||||||||||||||||||
| Zielgruppe des Ringversuchs | Clinical Chemistry Public & Private Labs | |||||||||||||||||||||||||||||||||
| Relevante Rechtsvorschriften oder Normen | ISO/IEC 17043:2023 | |||||||||||||||||||||||||||||||||
| Weitere Ziele | Post market surveillance of testing methods | |||||||||||||||||||||||||||||||||
| Teilnehmerzahl | ||||||||||||||||||||||||||||||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043:2023 |
|||||||||||||||||||||||||||||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | ||||||||||||||||||||||||||||||||||
| Kosten | ||||||||||||||||||||||||||||||||||
| Teilnahmegebühr | Contact provider for current fee, which depends on location and extent of service required. | |||||||||||||||||||||||||||||||||
| Regelmässig durchgeführt | Ja (Monthly (11 per year)) | |||||||||||||||||||||||||||||||||
| Der Ringversuch wird durchgeführt seit | 2005 | |||||||||||||||||||||||||||||||||
| Kontaktdaten des Anbieters | ||||||||||||||||||||||||||||||||||
| Anbieter | Kontaktperson | |||||||||||||||||||||||||||||||||
|
Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust
Queen Elizabeth Medical Centre P O Box 3909 B15 2SQ Birmingham United Kingdom Telefon: +44 121 414 7300 Fax: Web: https://www.birminghamquality.org.uk https://www.birminghamquality.org.uk |
Birmingham Quality
Telefon: +44 121 414 7300 Fax: E-Mail: birminghamquality@uhb.nhs.uk birminghamquality@uhb.nhs.uk |
|||||||||||||||||||||||||||||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.